Inhibikase Therapeutics, Inc. (NASDAQ: IKT)

Inhibikase Therapeutics, Inc., often symbolized as IBAK in the stock market, operates in the competitive pharmaceutical industry. The company focuses on developing protein kinase inhibitor therapeutics, aiming to modify the course of Parkinson's disease, Parkinson's-related disorders, and other diseases arising from Abelson Tyrosine Kinases. Its lead program, Risvodetinib (IkT-148009), is a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targeting the treatment of Parkinson's disease inside and outside the brain, as well as other diseases from Abelson Tyrosine Kinases.

Inhibikase Therapeutics generates revenue through the development and commercialization of its protein kinase inhibitor therapeutics. The company's primary products include Risvodetinib (IkT-148009) and IkT-001Pro. Risvodetinib (IkT-148009) is being developed as a treatment for Parkinson's disease and related disorders, while IkT-001Pro is being developed as a treatment for chronic myelogenous leukemia. The company has completed clinical development of Risvodetinib (IkT-148009) and is preparing to submit a new drug application (NDA) to the FDA, while IkT-001Pro is in clinical development, with a three-part dose finding/dose equivalence study in healthy volunteers having been completed.

In the pharmaceutical industry, Inhibikase Therapeutics holds a competitive advantage in developing protein kinase inhibitor therapeutics for Parkinson's disease and related disorders. Its lead program, Risvodetinib (IkT-148009), has shown promising results in clinical trials, positioning it to potentially become a best-in-class treatment for Parkinson's disease. However, the company faces substantial competition from various sources, including large and specialty pharmaceutical companies, academic research institutions, governmental agencies, and public and private research institutions.

Inhibikase Therapeutics has a strong team of principals and advisors with deep scientific, clinical, business, and leadership experience in drug development, including neurodegenerative diseases. The company has a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. to develop prodrug technology for protein kinase inhibitors, applicable for both oncology and non-oncology indications.

The company has received several grants from the United States Federal Government through the National Institutes of Health (NIH) to support the development of its lead program, Risvodetinib (IkT-148009), and its prodrug platform. Additionally, Inhibikase Therapeutics has received a contract from the Department of Defense to develop Medical Counter Measures to establish whether currently marketed inhibitors of c-Abl could act as multi-pathogen anti-infectives for bioterrorism defense.

While the company does not have any publicly disclosed customers, it has established relationships with several clinical research organizations, contract manufacturers, and sponsored research institutions to support its research and development activities.